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INTRODUCTION
Iodine has been used successfully in the final disinfection of drinking water in the Space
Shuttle Program. Since these flights are of relatively short duration and iodine has been widely
accepted as a disinfectant that can be used in emergency situations, there has been little concern
over health effects from this practice. As Space Station missions are extended in time, 90-180
days of exposure to iodine introduced in drinking water is envisioned. If the manned space
program is to continue to Mars and beyond, even longer missions might be anticipated. To
avoid the potentially disastrous results of outbreaks of infectious disease in the confined space
available in either the Space Station or other spacecraft, it would be generally beneficial to
maintain some minimal residual of iodine in the finished water as it is consumed. This would
prevent outgrowth of organisms in the storage and dispensing units on Space Station. However,
iodine hasnot been frequently employed in domestic water supplies because of fears of inducing
some longer term health hazards that are associated with elevated intakes of iodine, most
specifically congenital goiter (Wolff, 1969; Carswell, et al. 1970). These hazards remain rather
speculative, and the question remains as to howmuch iodine can remain in the water that is
consumed without resulting in a health hazard to the humans consuming the water.
Experiments conducted in rats found that administration of iodine as I- vs. 12 had opposite
effects on plasma thyroid hormone levels (Sherer, et al., 1991). 12 treated animals displayed
elevated thyroxine (T4) and thyroxine/triiodothyronine (T4/T3) ratios, whereas those treated with
I- displayed no change or reduced plasma concentrations of'I"4 at concentrations in drinking water
of 30 or 100 mg/L. Substantial differences were also observed in the uptake and distribution of
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radiodinein the body dependingupon whetherit wasadministeredas 1-or I20"tuall and Bull,
1990; Thrall et al., 1992a). Further study revealed that this effect was attributable in large part
to the reaction of 12 with metabolites of T4 in the gut of the rat to resynthesize "I'4 (Thrall et al.,
1992b). These data were in sharp contrast to the view that 12 and I" are essentially equivalent in
their effects on thyroid function (Gilman, et al., 1990). These data also suggest that it may not
be as necessary to control Iz concentrations in iodine disinfected drinking water to the same
levels as might be necessary to protect against the hypothyroid effects that arise from consuming
excessive I-.
The relative rate of thyroid hormone metabolism in humans and rats is known to be
significantly different, primarily because of a greater degree of binding of the hormone to plasma
proteins in humans. The turnover time of "1"4in humans varies between 5 and 9 days, whereas it
is 12-24 hours in rats (Hayes, et al., 1989). This would mean that the concentrations of
metabolites of thyroid hormones in the gut and available for reaction with I2 should be
significantly lower in humans than in rats.
Two experiments were designed to assess the hypothesis that similar effects would be
seen in humans as were observed in rats. The fast of these was a rising dose tolerance study,
examining the thyroid status of male volunteers exposed to single doses of water containing F or
12, up to a total dose of 1 mg/kg body weight. This was followed by a 14 day repeated dose
study utilizing total doses of iodine in the two forms at either 0.3 or 1.0 mg/kg body weight.
To adequately protect astronauts from the effects of iodine, it is essential to establish a
no-effect level for the residual forms of iodine left in the water as it is drunk. Therefore, these
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observations must be extended to lower doses. Traditionally, a safety factor of 3 to 10 would be
applied to a no-effect level to establish levels that would be safe. The possibility is still
anticipated that the effects of I2 and I- might be different at lower doses (i.e., the resynthesis of
thyroid hormone metabolites at low doses of I2 in humans would be limited by the amount of
metabolite present in the gastrointestinal tract, and could overcome the hypothyroid effects of
somewhat smaller doses of total iodine). An ability to maintain a higher residual of I2 in the
Space Station drinking water would provide an additional level of protection against waterborne
infectious disease in space.
METHODS AND MATERIALS
Study Population: Male students attending Washington State University OVSU), and
qualifying for health care services at the WSU Student Health Center, were eligible for inclusion
in the studies. Potential subjects were recruited through newspaper announcements and within
selected classes. Each individual was required to complete a brief medical history using a
standardized checklist. Any person reporting current, or a history of, any of the following
conditions was excluded from further consideration as a study subject: thyroid
disease/dysfunction; kidney problems/failure; heart disease/problems; malabsorption problems;
porphyria; liver disease; anorexia; surgery within the prior six months; gallbladder tests within
the prior two months; corticosteroid use within the prior two months; allergic reaction to iodine
or shell fish.
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Physical examinations were completed on the remaining potential subjects. The study
physician carefully looked for any indication of thyroid dysfunction (i.e., nodules, goiters) and
cardiovascular problems. Standard chemistry panels for blood (glucose, BUN, creatinine, uric
acids, calcium, phosphorus, cholesterol, triglycerides, total protein, albumin, globulin, AJG
ratio, total bilirubin, alkaline phosphatase, AST/SGOT, ALT/SGPT, GGT/GGTP, LDH,
sodium, potassium, and chloride) and urine were completed, as well as serum triiodothyronine
(T3), I'4, and thyroid stimulating hormone fiSH) levels to verify normal thyroid function. As an
additional precaution, potential subjects were given a thyroid autoantibody titre test as a
screening check for asymptomatic thyroid conditions/risks. After reviewing the screening and
test results, if the study physician found no reason to suspect the individual would respond
adversely to the iodine or iodide treatments proposed, he was admitted to the study.
Subject Requirements: Subjects were required to sign an informed consent form which
detailed the procedures and restrictions for the study. To minimize potential confounding of
study results, all subjects were required to eliminate alcohol, drugs (prescription,
over-the-counter, and illegal drugs), and goitrogen vegetables (turnips, rutabagas, cabbage,
cauliflower, brussels sprouts and broccoli) from their diet for two days prior to dosing, and
throughout the experiment.
Sample Size and Group Assitmrnent: Subjects, the study physician, and laboratory staff
were blinded to treatment group status of each individual. In the rising dose tolerance study, 32
subjects were randomly assigned to one of three treatment groups: 12 treatment, I- treatment, or a
control group. In the repeated dose study, 34 subjects were randomly assigned to one of five
4-
treatment groups: a high or low dose Iz treatment, a high or low dose 1- treatment, or a control
group (dose amounts described below).
Procedures
Su_ect Dosing Amounts and Procedures:
Experiment 1, Rising dose tolerance study: All procedures were performed at the WSU
Student Health Center under the supervision of the study physician and study coordinator.
Subjects assigned to the 12 treatment group received five rising doses of total iodine in phosphate
buffer over a 15 day period on consecutive Mondays and Thursdays as follows: Dose 1, 0.01
mg/kg body weight; dose 2, 0.03 mg/kg; dose 3, 0.10 mg/kg; dose 4, 0.30 mg/kg; dose 5, 1.0
mg/kg. Matched dose amounts of 1- in phosphate buffer were administered to the 1- treatment
group. The control group received distilled water with concentrations of NaCI matched to NaI
and phosphate buffer concentrations as noted below. Each of the doses were made up using
double-distilled/deionized water. To maintain a stable pH, doses for all treatment groups were
prepared with the following amounts of phosphate buffer (pH=6.95): Dose 1, 0.00 mM
phosphate buffer; dose 2, 0.10 mM phosphate buffer; dose3, 0.33 mM phosphate buffer; dose
4, 1.00 mM phosphate buffer; dose 5, 3.33 mM phosphate buffer. Each dose was mixed 24
hours prior to dosing. To help ensure subjects were blinded to their treatment group status, all
treatments were placed in brown pharmacy bottles, and treatments for the 1- and control groups
were tinted with yellow food coloring to approximate the color of the 12 treatments. Subjects
were required to fast from 9:00 p.m. the night prior to each dose until the two hour blood draw
following each dose. Fasting was not required prior to the 24 hour blood draws.
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Experiment 2, repeated dose study: Dose types and amounts include:
Treatment Groups Total Iodine Dose Pho_hate Buffer (DH = 6.95_
Iodine (I2) Low Dose
Iodine (12) High Dose
Iodide (1-) Low Dose
Iodide (1-) High Dose
Control
0.3 mg I2/kg body weight
1.0 mg I2/kg body weight
0.3 mg 1-&g body weight
1.0 mg 1-/kg body weight
1.0 mg NaC1/kg body weight
1.00 mM
3.33 mM
1.00 mM
3.33 mM
3.33 mM
Subjects assigned to the I2 treatment groups received 14 consecutive doses of 12 in phosphate
buffer over a 14 day period. Matched doses of I- in phosphate buffer were administered to the I"
treatment groups. To help ensure subjects
control group received distilled water with
concentrations of NaI in the high dose group.
food coloring and put in brown pharmacy
approximately the same color.
were blinded to their treatment group status, the
concentrations of NaC1 matched to the osmolar
Control and NaI solutions were tinted with yellow
bottles so that all treatment group doses were
A significant, but consistent amount (25 %) of I2 was converted to I" in the preparation of
the stock solutions. On each of the first two days of the study, subjects in the high dose I2 group
received I2 doses equal to 1 mg/kg body weight (i.e., 1.3 mg total iodine/kg). Subsequently, the
dose of I2 administered on days 3 through 14 was adjusted to 0.75 mg/kg per day (i.e., dose of 1
mg total iodine/kg per day). The elevated dose in the first two days led to a slightly larger time
weighted average dose in the high 12 group (1.05 mg/kg per day) than in the high dose 1r group.
The time weighted average for total iodine for the low dose I2 group, however, was consistently
greater (0.375 mg/kg/day) than in the iodide group (0.3 mg/kg/day). Tile data are provided as
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total iodinedosesin tablesandgraphs. Iodineconcentrationsweredeterminedusing the Leuco
Crystal Violet method(Franson,1985), and iodide was measuredutilizing an iodide specific
electrode. Thedosewasadjustedto thebody weightof eachindividual by appropriatechanges
in thevolumeof thestocksolutions(approximately200mgI2/L for thehigh dosegroup, and 70
mgI2/L for the low dosegroup.
Blood Collection: Student Health Services Staff nurses and phlebotomists were
responsible for all blood draws. Ten ml of blood was drawn from each subject 11 times in the
rising dose tolerance study, and four times in the repeated dose study. Blood drawn immediately
prior to dose one served as the baseline measure. The remaining draws in the rising dose/
tolerance study were taken at two hours and 24 hours following each of the five doses (day 0,
0.083, 1, 3,083; 4, 7.083, 8, 10.083, 11, 14.083, 15); the repeated dose study required two-
hour post-dose draws on days 7 and 14, and the last draw was taken 24 hours following the final
dose (day 0, 7.083, 14.083, 15.0).
Urine Collection: Urine specimens were collected at the initial screening physical
examination and the exit physical exam to assess iodide excretion levels in the rising dose
tolerance study. In the repeated dose study, urine samples were collected at baseline, and at 2
hours, 24 hours, 48 hours, and 72 hours following the final dose (dose 14) to assess the
excretion rate of iodide in the urine. Dietary salt intake was not restricted because the doses of
iodine administered during this study rendered the amount derived from consuming iodized salt
to insignificant amounts.
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Physician Evaluation and Sub_leer Follow-Up: The study physician and/or nursing staff
examined all subjects two hours following each treatment dose during the rising dose tolerance
study, and following dose 7 and dose 14 during the repeated dose study. Examinations included
vital signs, weight, a thyroid examination, and an appraisal of general well-being. There was
ongoing screening for adverse reactions and evidence of toxicity during each contact with the
physician to determine if any subject should be withdrawn from the study.
A study exit physical examination was given to all subjects approximately 10 days
following the final dose. This included a thyroid examination, vital signs, weight, and an overall
appraisal of subject well-being. Standard chemistry panels for blood (CHEM 19 as previously
described) and urine were again completed to verify that all values including T 3, "1"4and TSH
approximated the values obtained during each subject's entrance physical examination.
Analyses
Iodine Stability_: A stability study of each of the five dose levels of 12 was conducted.
The study involved preparing the five stock I2 solutions in a manner identical to the procedure
described above (see Subject Dosing and Amount Procedures - rising dose tolerance study). The
12 content of each dose was then followed over an 18 day period using a modified Leuco Crystal
Violet Method. Results of this analysis indicated the original concentrations were within 95 and
105% of the target concentrations and that the dosing solutions remained stable within + 10% of
the initial concentration during the course of both experiments.
Blood Analysis: Experiment 1, Repeated dose study: Total plasma "1"4 and T 3
concentrations were measured by RIA using the materials and methods provided in Amerlex kits
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(AmershamCorp., Arlington Heights, IL). Percent free T 4 and free T 3 were measured by
equilibrium dialysis of undiluted plasma at 37 C for I8 hr, as previously described by Young
(Young, et al., 1979). The free thyroid hormone concentrations were calculated as the product
of the total and percent free thyroid hormone.
Plasma TSH concentrations were measured by standard RIA double antibody procedures.
Primary antibody, reference preparation and purified hormone for radiolabeling were kindly
supplied by Dr. Salvatore Raiti of the NIDDK National Hormone and Pituitary Program, NIH
(Bethesda, MD). The radiolabel was prepared with lz_I using a modified lactoperoxidase-glucose
oxidase method and separated from free iodine on a Sephadex G-50 column.
Quality-control procedures were performed during every assay. Pooled plasma and a
"blank" control sample were included in every assay run. A complete standard curve generated
with each run of an assay was analyzed by computer utilizing log-logit data transformation
methods. Intra-assay variability was calculated for the quality-control samples with every assay.
In addition, inter-assay variance was analyzed by comparing quality-control samples from the
present assay with those of previous assays and with the cumulative average value for that
sample. Inter-assay standard deviation was calculated by an analysis of variance and was
compared with the average result obtained on all previous assays. Standard curves were run in
triplicate, whereas unknowns were assayed in duplicate.
Experiment 2, Repeated dose study: Total plasma 1"4, T3, TSH, and free T 4 levels were
measured with chemiluminescence immunometric assay methods using the materials and methods
provided in Nichols Institute Diagnostics kits (Nichols Institute Diagnostics, San luan
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Capistrano,CA 92675). This methodologygreatlysimplifiedtheprocessingof the samplesand
ensuredconsistentresults. Moreover, theseare thehighestqualityclinically valid immunoassay
testsavailable. These kits utilize the chemiluminescence of acridinium esters which emit light
upon treatment with hydrogen peroxide and an alkaline solution. The luminometer is set up to
automatically inject these solutions into the assay tubes. The oxidized acridinium ester is in an
excited state. The subsequent return to ground state results in the emission of light which is
quantified in two seconds, and is expressed in relative light units. These values are compared
with a standard curve prepared with assay validated standard containing the particular hormone
being measured. The concentration of the given hormone in the patient sample is determined
directly from the standard curve (Iogit-log data calculations).
Quality control procedures were performed during every assay. To assure accurate and
reliable results, included in each assay performed are validated controls with high, normal and
low hormone levels. These immunoassay controls standards (Lyphochek) were obtained from
BioRad ECS, (Anaheim CA). The values of these control standards values from each assay are
then compared with expected values to ensure precision and reproducibility of the assay. Intm-
assay variability was calculated for the quality control samples with every assay. In addition,
inter-assay variability was analyzed by comparing quality control samples from the present assay
with those of previous assays and with the cumulative average value for that sample. Inter-assay
standard deviation was calculated by an analysis of variance and was compared with the average
result obtained on all previous assays. Standard curves, control and unknown samples were run
in duplicate.
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_: Excretion of iodide in the urine was determined indirectly by normalizing
results with creatinine concentration of each subject's urine sample. Essentially this allows one
to determine what fraction of the day's urinary output the subject's urine sample represented in a
grab sample. Creatinine was measured using a diagnostic kit purchased from Sigma Chemical
Co. (St. Louis, MO, 63178). Iodide concentration of the subject's urine sample was then
determined using an I- selective electrode in combination with a double junction reference
electrode (Orion Research Co., Boston, MA
samples contamining 0.1 to 10 _tM iodide.
02129). Standard curves were prepared from
Urine samples were diluted (usually 1:10) with
double-distilled, deionized water and the signal obtained with the probe is compared to the
standard curve. Combining the results of the creatinine study and Y probe, a daily rate of r
excretion was calculated. It was assumed from the clinical literature (Sigma Diagnostic Kit
manual) that men excrete 1.95 g of creatinine over a 24 hour period.
Statistical Analysis: Statistical analyses were conducted using the Statistical Analysis
Software (SAS) Package, version 6.04 (SAS Institute Inc., Cary, NC). The data were analyzed
as a completely randomized design with a one-way treatment structure (treatment group) with
repeated measures. Tests of least significance difference were used to test for differences among
treatment group means if analysis of variance (ANOVA) P-values were < 0.05. If time by group
interaction was detected, group effects were analyzed at each time period. As previously
described, in the rising dose tolerance study, repeated measures were taken over I 1 time periods.
Response was measured at baseline, and at two hours and 24 hours following each of the five
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doses(day0, 0.083, 1, 3.083,4, 7.083, 8, 10.083, 11, 14.083, 15). The repeated dose study
measured response at four points in time: baseline, two hours post-dose on day 7, two hours
post-dose on day 14, and day 15 at exactly 24 hours following the final (14th) dose (day 0,
7.083, I4.083, I5.0).
RESULTS
Rising dose tolerance study: All subjects were male Caucasians, and ranged in age from
20 to 31 years old, with a mean of 22.9 years. There was no significant difference in age
between the three treatment groups (p=.79). Thirty-one subjects completed the study yielding a
97% (31/32) completion rate. One subject was required by the study physician to drop out of
the study at an early stage due to an ear infection which necessitated medication.
Figures la & b through 6a & b present the mean and standard error for T4, free "1"4,T3,
free T3, TSH, and the T4:T3 ratio at two hours (panels A) and 24 hours (panels B) after
administering each of the five doses of iodine as 12 or I. Table I presents the ANOVA results
for each thyroid hormone measured. Although time effects were observed, no time by group
interaction was detected. The only overall statistically significant difference observed was the
T4:T 3 ratio. Table 2 presents the pairwise comparison for T4:T3 among ti'eatment groups at each
post-dose period. These differences reflect a larger ratio in the group receiving F relative to the
controls, and to the 12 group 24 hours after doses 1, 2, and 3 (Figure 6b). Although these
differences were significant, no consistent findings were observed with increasing dose amounts.
None of the values in the 12 group were significantly different from the control group. A similar
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pattern was observed for free T4:T3 although not statistically significant, therefore, these data
have been omitted from the manuscript.
The mean excretion rates of iodide in the urine are provided in Figure 7. These data
include measurements from urine collected in the pre-experiment physical examination and post-
experiment physical examination for all groups. No significant differences were detected
between the three groups in either the pre-experiment physical examination (p = 0.78) or the
post-experiment physical examination (p = 0.89).
Repeated dose stua__: Tlfirty-three subjects completed the study yielding a 97 % (33/34)
completion rate. As in the rising dose tolerance study, the study physician ordered one subject
to drop out because of an infection which required medication.
Significant effects did become apparent with repeated administration of these same doses
(0.3 mg/kg, 1.0 mg/kg ) for a 14 day period. Most of the effects relate to thyroid hormone
status of the individuals, but there were also more non-specific effects of I2 that became apparent
in this experiment. Table 3 lists the frequency of responses to a questionnaire administered to
the subjects at the conclusion of the study. Positive responses were unique to the high and low
dose 12 groups. Individuals from these groups complained of a burning sensation in the throat.
This irritation was not evident on physical examination and, therefore, cannot technically be
termed a chemical burn. However, it is a response over which there should be some concern.
Clinical chemistries and physical examinations failed to identify any effects of either 12 or I" that
were unrelated to thyroid function.
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Figures8a & b through12a& b graphicallydepictthemeanand standarderror for T4,
freeT4,T3,TSH andtheT4:T3 ratio, respectively. Panel A of each figure compares the low and
high dose r groups to the control group; likewise, panel B compares the 12 groups to the control
group. Table 4 presents the ANOVA results for each thyroid hormone measured. Although
none of the overall group effects were statistically significant, interaction due to variation of
treatment groups over time was detected within the T 3 and TSH measures necessitating univariate
analysis of these two measures. A pairwise comparison for T3 among treatment groups found no
statistically significant effects at any of the individual time points. Table 5 presents the pairwise
comparison for TSH among treatment groups at each post-dose period. Statistically significant
increases are observed in both the high dose I2 group and the high dose I group compared to the
control group on day 15 (24 hours following the final dose administered on day 14). At the
lower doses, neither form of iodine produced increases that were statistically significant.
However, there was a comistent trend towards an increase with all doses which is difficult to
ignore. As presented in Table 5, p-values consistently moved closer towards significance with
each measurement: baseline, 0.58; day 7, 0.20, day 14, 0.08, day 15, 0.03. TSH levels did
largely return to control levels 10 days after treatment was suspended.
Urinary excretion of iodide was utilized primarily to be certain that iodine was cleared
from the system promptly after suspension of treatments. In Figure 13 it can be seen that the
excretion of iodine in steady-state had approached within 70% or more of the theoretical
maximum of the administered dose with all doses of iodine when examined 24 hours following
the last dose of iodine. The major descrepancy in this analysis was at 2 hours after the last high
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doseof iodide was admires" tered, where the rate of urinary elimination averaged only about 1/2
that expected. However, this lower level is in large part due to a lower rate measured in one
subject and there was a general trend towards a higher rate and a much tighter distribution in the
24 hour sample in tiffs same group. Within an additional 48 hours (i.e., 72 hours after
administration of iodine), the urinary excretion of iodide had essentially converged with the
levels seen in control subjects. Therefore, within the limits imposed by the utilization of grab
samples and correction of values to creatinine leveIs, rather than complete collections of urine, it
was concluded tha_ these data confirm the accuracy of the dosing schedule and demonstrate that
the subjects complied with the dosing schedule.
DISCUSSION
No substantive effects were obse_ed with either I2 or r administration in the rising dose
tolerance study. Throughout the study, the physician found no abnormalities that could be
related to the treatments, and there were no significant changes in clinical chemistry
measurements at exit physical examination. While the thyroid hormone levels in the blood of
individuals varied significaznfly in time, the mean values of groups tracked well with one another
and no interaction was detected. The day-to-day variation in thyroid hormone levels probably
reflected small, systematic interassay variation and/or changes in environmental conditions that
affected all subjects in an equivalent way. Thus, it may be concluded that single acute doses of
12 or F up to 1 mg/kg of body weight have minimal effects on thyroid function in normal
humans.
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Both specificandnon-specificeffectsof iodine werenotedin the repeated dose study. 12
produced the only non-specific effect of importance, the sensation of a "burned" throat. This
effect might be expected from consumption of iodine since high concentrations are known to
damage mucous membranes (Gosselin, et al., 1976). However, this effect was not reflected in
clinical observations so it should not be considered a chemical burn as such. More than likely it
reflects and significant degree of irritation to the mucous membranes that is more closely related
to the concentrations of the solutions of iodine that were administered rather than the actual dose
of iodine. High concentrations were used in this study primarily for the purpose of ensuring
compliance by observing the actual consumption of the water. Nevertheless, it should be noted
that 70 and 200 mg/L concentrations of iodine would never be achieved in Space Station water.
The daily administration of repeated doses of 12 and 1- in the range of 0.3 to 1 mg total
iodine/kg for a period of 14 days does induce changes in thyroid hormone status. Decreases in
"1"4 were observed with dose schedules with Y and 12, but none were statistically significant
compared to each other, or compared to the control group (Figure 8a & b). TSH was
significantly increased by the high dose of both 12 and I', but in this case the effects of the high
dose schedule of 12 were substantively greater than that seen with I-. It may well be that these
differences do reflect some underlying differences between 12 and 1-, but the statistical power of
this experiment does not allow a clear conclusion in this area.
Depression of 1"4 levels was not observed in either male or female rats with
concentrations of 12 or I of up to 100 mg/L for 100 days. There was, however, an increase in
thyroid weights that approached statistical significance at the highest dose of I- in male rats.
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TSH wasnot measuredin theseexperiments,but this latter result would be consistentwith an
increasein TSH levels. It wasanticipatedfrom the prior studiesin rats (Sherer,et al., 1991;
Thrall andBull, 1990;Thrall, et al., 1992a& b) that therewould be somedivergencebetween
the effectsof iodine administeredas12vs I-. It waspredictedthat at somelow doseof iodine,
administrationof 12would preserve,or evenincreasethe levelsof circulating "1"4, and increase
the "1"4to T 3 ratio. There is no clear indication of such a differential effect in the present study.
There may be several reasons for this divergence. First, it is quite clear that the rate of thyroid
hormone turnover in humans is much less than that observed in rodents. This would result in
lower concentrations of thyroid hormone metabolites that would be available in the
gastrointestinal tract for reaction with administered 12. Thus, the doses of iodine chosen may
have been too high relative to the levels of available substrate. In this case, the effects of the
actual doses of I2 administered may have been simply swamped out by the overwhelming and
well established effect of elevated consumption of total iodine. A second possibility is simply
that there is inadequate amount of substrate available in the human gastrointestinal tract for this
phenomena to have a substantive impact on thyroid hormone levels in humans_
There are trends in the data which suggest that such interaction could still play a little
more important role at lower doses of 12 and I-. For example, the T4 levels in I2-treated
volunteers are below that of control at the low dose when it was administered for 14 days, but
they are still greater than the levels observed in I" treated groups. However, this interpretation is
considerably clouded by the fact that TSH levels were increased early and to a greater extent
with 12 than was observed with equivalent levels of I'. Thus, the increases in "1"4levels could
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result from higherTSH concentrations. Second, there is absolutely no hint of such an effect in
the rising dose tolerance study. Therefore, the only conclusion that can be made from the
present study is that there are insufficient '1'4 precursors in the human intestine to allow for this
mechanism to occur. In a formal sense, this issue can only be resolved by further investigation
of the impact of chronic intake of lower levels of iodine than are employed in the present study
on thyroid hormone status in htunansl
The minor variations in plasma "I'4 and T 3 levels observed in the present study have
minimal implications for long-term adverse health effects in themselves. However, some
problems might be associated with consistently elevated plasma TSH concentrations. This could
have more serious long-term impacts on health that might be considered more fully in future
studies. Health concerns that might arise from these effects would include goiter, and increased
risk from cancer of the thyroid (Williams, et al., 1977; Hill, et al., 1989; Edmonds and Tellez,
1988), but there may also be other less well defined alterations in the function of other endocrine
organs (Thomas, et al., 1987).
In addition to these traditionally recognized effects of elevated TSH, it is important to
remember that nonphysiologic elevations of pituitary TSH secretion primarily results from the
hypersecretion of the hypothalamic neurohormone thyrotropin-releasing-hormone (TRI0 and this
is associated with a number of pathological conditions in both men and women. An example of
one of these conditions is hyperprolactinemi'a, which is characterized by numerous clinical
manifestations including headaches, reproductive dysfunction, visual disorders and gynecomastia
(Molitch and Reichlin, 1985).
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In summary,the present experiment in humans failed to confirm the differential effect of
12 on maintenance of serum I"4 concentrations relative to the effects of I" that was observed in
prior experiments in rats. The reaction of I2 with metabolites of thyroid hormones in the
intestine that appears responsible for this effect in rats probably also exists at some level in
humans. The present results suggest that the concentrations of such metabolites in the human
intestinal tract are too small to significantly affect circulating concentrations of T4. However,
based on the elevations in TSH, there should be some concem over the potential impacts of
chronic consumption of iodine in drinking water.
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Figure 1. Effects of iodine treatments
on serum T4 - 2 hours after dose
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Figure 2. Effects of iodine treatments
on serum free T4 - 2 hours after dose
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Figure 3. Effects of iodine treatments
on serum T3 - 2 hours after dose
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Figure4. Effectsof iodine treatments
on serum free T3 - 2 hours after dose
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Figure 5. Effects of iodine treatments
on serum TSH - 2 hours after dose
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Figure 6, Effects of iodine treatments
on T4/T3 ratio - 2 hours after dose
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Table 1
Experiment 1, Rising Dose Tolerance Study
Analysis of Variance for Repeated Measures: P-Values
(n=31)
Time Time by Group
Effect Group Effect Effect
T4 0.0001 0.7142 0.1000
Free I'4 0.0001 0.0893 0.0709
T3 0.0001 0.5729 0.9754
Free T3 0.0001 0.1120 0.7966
TSH 0.0001 0.4610 0.9536
T4:Ts 0.0001 0.1932 0.0372
Free T4:Free "I'3 0.0031 0.4655 0.2935
Table 2
Experiment 1, Rising Dose Tolerance Study
T4:T3 Univariate ANOVA with Least Significant Differences
(nffi31)
T :T3 P-Value
. Group Differences
Iodine to Iodide to
Control Control
Iodine to
Iodide
Baseline
Dose 1, 0.01 mg/kg body wt
2 hours post-dose
24 hours post-dose
Dose 2, 0.03 mg/kg body wt
2 hours post-dose
24 hours post-dose
Dose 3, 0.1 mg/kg body wt
2 hours post-dose
24 hours post-dose
Dose 4, 0.3 mg/kg body wt
2 hours post-dose
24 hours post-dose
Dose 5, 1.0 mg/kg body wt
2 hours post-dose
24 hours post-dose
0.7703
0.7251
0.0054
0.1148
0.0156
0.2995
0.0028
0.0771
0.2116
0.1537
0.0598
+
+
+
+
+
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Figure 7. Exp. 1: Rising dose tolerance
study - urinary iodide excretion
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Table 3
Experiment 2, Repeated Dose Study
Adverse Reactions Unique to the Iodine (I_) Treatment Groups
Adverse Reaction
Treatment Group*
Low Dose I2 High Dose I2
(n=6) (n=7)
Yes Yes
Burned lips 0 1
Burned throat 4 5
Burned esophagus 2 1
Hoarseness 0 1
Light-headed after any dose 1 2
Hushed 0 1
Upset stomach 0 2
Abdominal pain 0 2
Tachycardia 1 0
Dizziness 1 0
Nausea 0 1
Excessive drooling 0 1
Colder than usual 1 1
Hotter than usual 0 1
Constipation 0 1
Irritated nasal passage 1 0
* Low dose = 0.3 mg/kg body weight
High dose = 1.0 mg/kg body weight
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Figure 8. Effect of iodine treatments
on serum T4 - Iodide X 14 days
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Figure 9. Effect of iodine treatments
on free T4 - Iodide X 14 days
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Figure 10. Effect of iodine treatments
on T3 - Iodide X 14 days
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Figure 11. Effect of iodine treatments
on serum TSH - Iodide X 14 days
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Figure 12. Effect of Repeated Doses of
iodine on T4/T3 ratio - Iodide X 14 days
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Table 4
Experiment 2, Repeated Dose Study
Analysis of Variance for Repeated Measures: P-Values
(n=32)
Thyroid
Hormone
Time Time by Group
Effect Group Effect Effect
"1"4 0.0001 0.1622 0.4332
Free T4 0.0001 0.4394 0.1534
"1"3 0.0001 0.0031 0.9742
TSH 0.0001 0.0008 0.1255
"1"4:'1"3 0.0001 0.1133 0.3040
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Figure 13. Urinary excretion of iodine
in repeated dose study - Iodide X 14 d
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